List of Excipients in Branded Drug SERTRALINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	CELLULOSE, MICROCRYSTALLINE
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	CROSCARMELLOSE SODIUM
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	FD&C YELLOW NO. 5
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	GELATIN
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	HYDROXYPROPYL CELLULOSE
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	MAGNESIUM STEARATE
Almatica Pharma LLC	SERTRALINE HCL	sertraline hydrochloride	52427-664	SILICON DIOXIDE

Generic Drugs Containing SERTRALINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	FD&C BLUE NO. 2
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	HYDROXYPROPYL CELLULOSE
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	HYPROMELLOSE 2910
Hikma Pharmaceuticals USA Inc	sertraline hydrochloride	0143-9656	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in SERTRALINE?

# Of NDCs	Excipient
32	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
3	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
3	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
52	CELLULOSE, MICROCRYSTALLINE
1	CI 42090
3	CI 77891
7	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for Sertraline

Last updated: February 25, 2026

What is the role of excipients in sertraline formulation?

Excipients in sertraline formulations serve to enhance stability, bioavailability, and manufacturability. Common excipients include microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate, and film coatings such as hypromellose. These components influence drug release profiles, shelf-life, and patient tolerability.

How does excipient choice affect bioavailability and stability?

The formulation's excipient profile impacts pharmacokinetics by altering dissolution and absorption. For sertraline, a selective serotonin reuptake inhibitor (SSRI), ensuring consistent bioavailability is crucial. Excipients like povidone improve solubility, whereas hypromellose can control release. Stability concerns involve excipients that prevent degradation due to moisture or light, such as desiccants and protective coatings.

What are the current excipient trends in sertraline manufacturing?

Manufacturers are shifting toward excipients that enable generic combination products and extend shelf life:

• Enhanced bioavailability: Using solubilizers or permeability enhancers.
• Reduced excipient load: To minimize adverse reactions, especially in pediatric formulations.
• Modified-release systems: Employing hydrophilic polymers (e.g., HPMC) for controlled release.

Regulatory preferences favor excipients with well-characterized safety profiles, such as cellulose derivatives and lactose. Some companies explore plant-based or allergen-free excipients to target niche markets.

What commercial opportunities exist with excipient innovations?

1. Formulation differentiation: Introducing controlled-release sertraline tablets with proprietary excipient matrices can command premium pricing.
2. Pediatric formulations: Utilizing excipients suitable for children, like taste-masked microgranules, opens growth markets.
3. Oral dispersible films: Using fast-dissolving excipients enhances patient compliance and expands product lines.
4. Extended Shelf Life: Incorporation of stabilizing excipients allows longer storage, reducing supply chain costs and expanding distribution.

Market data indicates a Compound Annual Growth Rate (CAGR) of approximately 5% for SSRI formulations, with excipient innovations contributing to higher margins in generics and branded drugs alike.

Competitive landscape

Leading pharmaceutical companies invest in excipient R&D, focusing on bioavailability and stability enhancements. Contract manufacturing organizations (CMOs) offer custom excipient blends tailored for sertraline, creating a competitive edge for patent holders and generic producers.

Regulatory considerations

Excipients must meet pharmacopoeial standards (USP, EP, JP). Regulatory agencies, including the FDA, scrutinize excipient safety, particularly for novel or rarely used components. The use of GRAS (Generally Recognized as Safe) excipients accelerates approval processes, while proprietary excipients require detailed safety data.

Strategic recommendations

• Prioritize research into controlled-release excipient matrices.
• Develop pediatric and specialized formulations with suitable excipients.
• Engage regulatory expertise to streamline approval for novel excipients.
• Leverage partnerships with excipient suppliers for innovation and cost savings.

Key Takeaways

• Excipient selection deeply influences sertraline's bioavailability, stability, and patient adherence.
• Innovations in excipient technology create opportunities for product differentiation and market expansion.
• Regulatory compliance and safety profiles remain critical in excipient selection.
• Developing formulations targeting niche segments, such as pediatrics and controlled release, can command higher prices.
• Collaborations with excipient developers can reduce time-to-market and enhance formulation performance.

FAQs

1. Can novel excipients improve sertraline bioavailability?
Yes, excipients like permeation enhancers or solubilizers can increase dissolution rates and absorption, potentially lowering effective doses.

2. What excipients are preferred for controlled-release sertraline formulations?
Hydrophilic polymers such as hypromellose or ethylcellulose are standard for creating sustained-release systems.

3. Are there safety concerns with excipients in sertraline products?
Excipients must comply with pharmacopeial standards; any novel excipient needs extensive safety data and regulatory approval.

4. How do excipient choices impact manufacturing costs?
Simpler, well-established excipients typically reduce costs and regulatory hurdles but may limit innovation; specialized excipients increase costs but enable differentiation.

5. Is there market demand for specific excipient-based formulations?
Yes, especially in pediatric, geriatric, and controlled-release markets. Formulations with improved dosing convenience often meet consumer and prescriber preferences.

---

References

[1] U.S. Pharmacopeia. (2022). USP-NF General Chapters <1079> and <381>.
[2] European Pharmacopoeia. (2023). Monographs on excipients.
[3] Grant, D. J., & Patel, J. (2020). Pharmaceutical excipients: Properties, selection, and application. International Journal of Pharmaceutical Sciences, 12(4), 215–230.
[4] Smith, R. M., & Jones, A. L. (2021). Innovations in controlled-release formulations. Journal of Drug Delivery Science and Technology, 62.